Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment

被引:27
|
作者
Gomez, Anna [1 ]
Ferrer, Isidre [1 ]
机构
[1] Univ Barcelona, IDIBELL Hosp Univ Bellvitge, Serv Anat Patol, Inst Neuropatol,CIBERNED, Lhospitalet De Llobregat 08907, Spain
关键词
Parkinson disease; LRRK2; alpha-Synuclein; Oxidative stress; Glial fibrillary acidic protein; Superoxide dismutase; AUTOSOMAL-DOMINANT PARKINSONISM; PHOSPHORYLATED ALPHA-SYNUCLEIN; FIBRILLARY ACIDIC PROTEIN; LEWY-BODY; OXIDATIVE DAMAGE; TRANSGENIC MICE; S-NITROSYLATION; AGGREGATION; GENE; NITRATION;
D O I
10.1007/s00401-010-0669-y
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Previous studies have shown altered synuclein, increased oxidative stress damage and increased oxidative stress responses in patients with sporadic Parkinson's disease (PD) without cognitive impairment. Yet no information exists about possible molecular alterations in the cerebral cortex in familial PD. The present study shows abnormal alpha-synuclein solubility and aggregation, and aggregated nitrated alpha-synuclein, in the cerebral cortex (area 8) in cases with long-lasting PD linked with the G2019S LRRK2 mutation, one of them with a few Lewy bodies (LBs) and the other two without LBs in the cerebral cortex. Increased expression of the oxidative stress marker malondialdehyde-lysine (MDAL), together with increased oxidative stress responses, AGE receptors (RAGE) and superoxide dismutase 2, occurred in the frontal cortex in the three LRRK2 cases compared with three controls processed in parallel. Bi-dimensional gel electrophoresis, western blotting, in-gel digestion and mass spectrometry disclosed glial fibrillary acidic protein as a target of MDAL adducts. Tubulin beta 4 and enolase 2 were also identified as targets of oxidative damage. These results demonstrate biochemical abnormalities of alpha-synuclein, and increased oxidative stress damage and oxidative stress responses in the frontal cortex in PD linked with G2019S LRRK2 mutation not related with the presence of cortical LBs and in the absence of apparent cognitive deficits. These findings show that the cerebral cortex in familial PD linked with G2019S LRRK2 is affected in a similar way than that seen in sporadic PD without cognitive impairment.
引用
收藏
页码:155 / 167
页数:13
相关论文
共 50 条
  • [21] Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy
    De Rosa, Anna
    Criscuolo, Chiara
    Mancini, Pietro
    De Martino, Marina
    Giordano, Aria Anna
    Pappata, Sabina
    Filla, Alessandro
    De Michele, Giuseppe
    PARKINSONISM & RELATED DISORDERS, 2009, 15 (03) : 242 - 244
  • [22] The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation
    Hassin-Baer, Sharon
    Laitman, Yael
    Azizi, Esther
    Molchadski, Irena
    Galore-Haskel, Gilli
    Barak, Frida
    Cohen, Oren S.
    Friedman, Eitan
    JOURNAL OF NEUROLOGY, 2009, 256 (03) : 483 - 487
  • [23] The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition
    Kelly, Kaela
    Wang, Shijie
    Boddu, Ravindra
    Liu, Zhiyong
    Moukha-Chafiq, Omar
    Augelli-Szafran, Corinne
    West, Andrew B.
    EXPERIMENTAL NEUROLOGY, 2018, 309 : 1 - 13
  • [24] Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity
    An Phu Tran Nguyen
    Tsika, Elpida
    Kelly, Kaela
    Levine, Nathan
    Chen, Xi
    West, Andrew B.
    Boularand, Sylviane
    Barneoud, Pascal
    Moore, Darren J.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (29) : 17296 - 17307
  • [25] Motor Phenotype of LRRK2 G2019S Carriers in Early-Onset Parkinson Disease
    Alcalay, Roy N.
    Mejia-Santana, Helen
    Tang, Ming Xin
    Rosado, Llency
    Verbitsky, Miguel
    Kisselev, Sergey
    Ross, Barbara M.
    Louis, Elan D.
    Comella, Cynthia L.
    Colcher, Amy
    Jennings, Danna
    Nance, Martha A.
    Bressman, Susan
    Scott, William K.
    Tanner, Caroline
    Mickel, Susan F.
    Andrews, Howard F.
    Waters, Cheryl H.
    Fahn, Stanley
    Cote, Lucien J.
    Frucht, Steven J.
    Ford, Blair
    Rezak, Michael
    Novak, Kevin
    Friedman, Joseph H.
    Pfeiffer, Ronald
    Marsh, Laura
    Hiner, Bradley
    Siderowf, Andrew
    Caccappolo, Elise
    Ottman, Ruth
    Clark, Lorraine N.
    Marder, Karen S.
    ARCHIVES OF NEUROLOGY, 2009, 66 (12) : 1517 - 1522
  • [26] The Impact of LRRK2 G2019S on Parkinson's Disease: Clinical Phenotype and Treatment in Tunisian Patients
    Barreh, Guedi Ali
    Sghaier, Ikram
    Abida, Youssef
    Gharbi, Alya
    Nasri, Amina
    Mrabet, Saloua
    Souissi, Amira
    Ben Djebara, Mouna
    Trabelsi, Sameh
    Kacem, Imen
    Gargouri-Berrechid, Amina
    Gouider, Riadh
    JOURNAL OF MOVEMENT DISORDERS, 2024, 17 (03) : 294 - 303
  • [27] G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice
    Novello, Salvatore
    Arcuri, Ludovico
    Dovero, Sandra
    Dutheil, Nathalie
    Shimshek, Derya R.
    Bezard, Erwan
    Morari, Michele
    NEUROBIOLOGY OF DISEASE, 2018, 120 : 21 - 33
  • [28] Prevalence of Cancer in Parkinson's Disease Related to R1441G and G2019S Mutations in LRRK2
    Ruiz-Martinez, Javier
    de la Riva, Patricia
    Rodriguez-Oroz, Maria C.
    Mondragon Rezola, Elisabet
    Bergareche, Alberto
    Gorostidi, Ana
    Gago, Belen
    Estanga, Ainara
    Larranaga, Nerea
    Sarasqueta, Cristina
    Lopez de Munain, Adolfo
    Marti Masso, Jose F.
    MOVEMENT DISORDERS, 2014, 29 (06) : 750 - 755
  • [29] The LRRK2 R1441C Mutation is More Frequent Than G2019S in Parkinson's Disease Patients from Southern Italy
    Criscuolo, Chiara
    De Rosa, Anna
    Guacci, Anna
    Simons, Erik J.
    Breedveld, Guido J.
    Peluso, Silvio
    Volpe, Giampiero
    Filla, Alessandro
    Oostra, Ben A.
    Bonifati, Vincenzo
    De Michele, Giuseppe
    MOVEMENT DISORDERS, 2011, 26 (09) : 1733 - 1736
  • [30] Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers
    Fraser, Kyle B.
    Moehle, Mark S.
    Alcalay, Roy N.
    West, Andrew B.
    NEUROLOGY, 2016, 86 (11) : 994 - 999